S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella,Jun Xu,David M. Barrett,Joseph A. Fraietta,Tyler J. Reich,David E Ambrose,Michael Klichinsky,Olga Shestova,Prachi R. Patel,Irina Kulikovskaya,Farzana Nazimuddin,Vijay Bhoj,Elena Orlando,Terry J. Fry,Hans Bitter,Shannon L. Maude,Bruce L. Levine,Christopher L. Nobles,Frederic D. Bushman,Regina M. Young,John Scholler,Saar Gill,Carl H. June,Stephan A. Grupp,Simon F. Lacey,J. Joseph Melenhorst +25 more
TL;DR: A patient relapsing 9 months after CD19-targeted CAR T cell infusion with CD19– leukemia that aberrantly expressed the anti-CD19 CAR was reported.
Journal ArticleDOI
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena Orlando,Xia Han,Catherine Tribouley,Patricia A. Wood,Rebecca Leary,Markus Riester,John E. Levine,Muna Qayed,Stephan A. Grupp,Michael Boyer,Barbara De Moerloose,Eneida R. Nemecek,Henrique Bittencourt,Hidefumi Hiramatsu,Jochen Buechner,Stella M. Davies,Michael R. Verneris,Kevin Nguyen,Jennifer Brogdon,Hans Bitter,Michael Morrissey,Piotr Pierog,Serafino Pantano,Jeffrey A. Engelman,Wendy Winckler +24 more
TL;DR: Mutations in the CD19 gene suggesting irreversible loss of its surface expression are identified in the majority of analyzed cases of CD19– relapse in two clinical trials of pediatric ALL CD19 CAR T therapy, offering considerations for the rational choice of follow-up therapies.
Journal ArticleDOI
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
Julie C. Fitzgerald,Scott L. Weiss,Shannon L. Maude,David M. Barrett,Simon F. Lacey,J. Joseph Melenhorst,Pamela A. Shaw,Robert A. Berg,Carl H. June,David L. Porter,Noelle V. Frey,Stephan A. Grupp,David T. Teachey +12 more
TL;DR: Clinicians should be aware of expanding use of this breakthrough therapy and implications for critical care units in cancer centers and the timing, severity, and intensive care management of cytokine release syndrome after chimeric antigen receptor–modified T cell therapy.
Journal ArticleDOI
Chimeric Antigen Receptor Therapy for Cancer
TL;DR: This new form of targeted immunotherapy merges the exquisite targeting specificity of monoclonal antibodies with the potent cytotoxicity and long-term persistence provided by cytotoxic T cells to create an entirely new arena for targeted therapy of cancer.
Journal ArticleDOI
CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia
Haydar Frangoul,David Altshuler,M. Domenica Cappellini,Yi-Shan Chen,Jennifer Domm,Brenda K. Eustace,Juergen Foell,la Fuente Josu de,Stephan A. Grupp,Rupert Handgretinger,Tony W. Ho,Antonis Kattamis,Andrew Kernytsky,Julie A. Lekstrom-Himes,Amanda M. Li,Franco Locatelli,Markus Y. Mapara,Montalembert Mariane de,Damiano Rondelli,Akshay Sharma,Sujit Sheth,Sandeep Soni,Martin H. Steinberg,Donna A. Wall,Angela Yen,Selim Corbacioglu +25 more